Inclusion Criteria:

1.Histological or cytological diagnosis of lung squamous cell carcinoma of stage IIB and
IIIA.

2.18 years or older 3.ECOG Performance Status no more than 2; 4.Appraisable disease, the
presence of at least three lesions if longest diameter <10 mm by brain MRI; 5.Haemoglobin
10.0 g/dl, Absolute neutrophil count (ANC) 1.5 x 10E9/L, platelets 100 x 10E9/L; 6.Total
bilirubin 1.5 x upper limit of normal (ULN); 7.ALT and AST < 2.5 x ULN in the absence of
liver metastases, or < 5 x ULN in case of liver metastases; 8.Creatinine clearance
60ml/min (calculated according to Cockcroft-gault formula).

Exclusion Criteria:

1. Any systemic anticancer treatment for NSCLC

2. Local radiotherapy for NSCLC.

3. In this study within five years prior to the start of treatment with other than NSCLC
patients with other cancers.

4. Any instability in systemic disease, including: active infection, absence of control
hypertension, unstable angina, begins in the last 3 months of angina pectoris,
congestive heart failure

5. HIV infection;

6. Allergic to paclitaxel or Platinum;

7. mixed with adenocarcinoma, small cell lung cancer;

8. Pregnant or lactating women;

9. Other researchers believe that does not fit into the group